Neurocrine Biosciences reported $754.1M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Agios Pharmaceuticals USD 19.93M 3.58M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Cytokinetics USD 25.96M 5.45M Sep/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Exelixis USD 30.83M 8.23M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
Halozyme Therapeutics USD 33.55M 9.94M Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Prothena USD 1.69M 249K Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Repligen USD 27.7M 5.54M Sep/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Teva Pharmaceutical Industries USD 2.55B 170M Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026